These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 21765463)

  • 1. Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma.
    de Lange J; Ly LV; Lodder K; Verlaan-de Vries M; Teunisse AF; Jager MJ; Jochemsen AG
    Oncogene; 2012 Mar; 31(9):1105-16. PubMed ID: 21765463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inability of p53-reactivating compounds Nutlin-3 and RITA to overcome p53 resistance in tumor cells deficient in p53Ser46 phosphorylation.
    Ma T; Yamada S; Ichwan SJ; Iseki S; Ohtani K; Otsu M; Ikeda MA
    Biochem Biophys Res Commun; 2012 Jan; 417(3):931-7. PubMed ID: 22166212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
    Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
    Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RITA inhibits multiple myeloma cell growth through induction of p53-mediated caspase-dependent apoptosis and synergistically enhances nutlin-induced cytotoxic responses.
    Saha MN; Jiang H; Mukai A; Chang H
    Mol Cancer Ther; 2010 Nov; 9(11):3041-51. PubMed ID: 21062913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill.
    Xie X; He G; Siddik ZH
    Mol Pharmacol; 2020 Apr; 97(4):237-249. PubMed ID: 32063580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.
    Kojima K; Konopleva M; McQueen T; O'Brien S; Plunkett W; Andreeff M
    Blood; 2006 Aug; 108(3):993-1000. PubMed ID: 16543464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells.
    Miyachi M; Kakazu N; Yagyu S; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H
    Clin Cancer Res; 2009 Jun; 15(12):4077-84. PubMed ID: 19509161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM) on the chemosensitivity of mantle cell lymphoma to agents that induce DNA strand breaks.
    Golla RM; Li M; Shen Y; Ji M; Yan Y; Fu K; Greiner TC; McKeithan TW; Chan WC
    Hematol Oncol; 2012 Dec; 30(4):175-9. PubMed ID: 22170260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma.
    Di Marzo D; Forte IM; Indovina P; Di Gennaro E; Rizzo V; Giorgi F; Mattioli E; Iannuzzi CA; Budillon A; Giordano A; Pentimalli F
    Cell Cycle; 2014; 13(4):652-65. PubMed ID: 24345738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nutlin-3, an Hdm2 antagonist, inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated inactivation of HIF-1alpha.
    Lee YM; Lim JH; Chun YS; Moon HE; Lee MK; Huang LE; Park JW
    Carcinogenesis; 2009 Oct; 30(10):1768-75. PubMed ID: 19696166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small-molecule activation of p53 blocks hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in vivo and leads to tumor cell apoptosis in normoxia and hypoxia.
    Yang J; Ahmed A; Poon E; Perusinghe N; de Haven Brandon A; Box G; Valenti M; Eccles S; Rouschop K; Wouters B; Ashcroft M
    Mol Cell Biol; 2009 Apr; 29(8):2243-53. PubMed ID: 19223463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abrogation of Wip1 expression by RITA-activated p53 potentiates apoptosis induction via activation of ATM and inhibition of HdmX.
    Spinnler C; Hedström E; Li H; de Lange J; Nikulenkov F; Teunisse AF; Verlaan-de Vries M; Grinkevich V; Jochemsen AG; Selivanova G
    Cell Death Differ; 2011 Nov; 18(11):1736-45. PubMed ID: 21546907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation.
    Zheng T; Wang J; Chen X; Meng X; Song X; Lu Z; Jiang H; Liu L
    Tumour Biol; 2010 Aug; 31(4):287-95. PubMed ID: 20422343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination.
    Cheok CF; Dey A; Lane DP
    Mol Cancer Res; 2007 Nov; 5(11):1133-45. PubMed ID: 18025259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents.
    Michaelis M; Rothweiler F; Agha B; Barth S; Voges Y; Löschmann N; von Deimling A; Breitling R; Doerr HW; Rödel F; Speidel D; Cinatl J
    Cell Death Dis; 2012 Apr; 3(4):e294. PubMed ID: 22476102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chk2 mediates RITA-induced apoptosis.
    de Lange J; Verlaan-de Vries M; Teunisse AF; Jochemsen AG
    Cell Death Differ; 2012 Jun; 19(6):980-9. PubMed ID: 22158418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The therapeutic potential of p53 reactivation by nutlin-3a in ALK+ anaplastic large cell lymphoma with wild-type or mutated p53.
    Drakos E; Atsaves V; Schlette E; Li J; Papanastasi I; Rassidakis GZ; Medeiros LJ
    Leukemia; 2009 Dec; 23(12):2290-9. PubMed ID: 19741726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma.
    Wu CE; Esfandiari A; Ho YH; Wang N; Mahdi AK; Aptullahoglu E; Lovat P; Lunec J
    Br J Cancer; 2018 Feb; 118(4):495-508. PubMed ID: 29235570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of endogenous p53 by combined p19Arf gene transfer and nutlin-3 drug treatment modalities in the murine cell lines B16 and C6.
    Merkel CA; da Silva Soares RB; de Carvalho AC; Zanatta DB; Bajgelman MC; Fratini P; Costanzi-Strauss E; Strauss BE
    BMC Cancer; 2010 Jun; 10():316. PubMed ID: 20569441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs nutlin-3 and RITA.
    Rinaldo C; Prodosmo A; Siepi F; Moncada A; Sacchi A; Selivanova G; Soddu S
    Cancer Res; 2009 Aug; 69(15):6241-8. PubMed ID: 19638586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.